Market Drivers of the Proton Therapy Systems Market
The increasing incidence of cancer and the rising demand for innovative cancer treatments are significant factors driving the growth of the proton therapy systems market. According to the International Agency for Research on Cancer (IARC), the most commonly diagnosed cancers in 2022 included lung, breast, and prostate cancers, with incidence rates of 23.6, 47.1, and 29.4 cases per 100,000 individuals, respectively. IARC estimates suggest that the total number of cancer cases will rise from 19.98 million in 2022 to 23.71 million by 2030, and further to 30.97 million by 2045. Certain cancer types, particularly head and neck cancers (including nasal, oral, eye, and laryngeal cancers) and brain tumors, require specialized treatment approaches, leading to an increased demand for advanced therapies like intensity-modulated proton therapy (IMPT). Traditional radiation therapies, such as X-ray radiation, often expose healthy tissues surrounding tumors to radiation, resulting in side effects and potential secondary cancers. In contrast, proton therapy effectively targets complex tumors in the brain and head and neck regions while minimizing damage to adjacent healthy tissues. Therefore, the high prevalence of cancer and the need for sophisticated treatment options are propelling the growth of the proton therapy systems market.
Opportunities in the Proton Therapy Systems Market
Emerging economies, including India, China, Argentina, Brazil, the UAE, and South Africa, present substantial growth opportunities for stakeholders in the proton therapy systems market. This growth is driven by increasing disposable incomes, a rising population of cancer patients, enhanced research and development activities, improved healthcare infrastructure, heightened awareness of diseases, and comparatively relaxed regulations compared to developed nations. The rising cancer incidence in these regions is leading to a greater demand for proton therapy and other cancer treatment modalities. Additionally, governments in these countries are prioritizing access to effective and advanced healthcare services for larger segments of their populations, along with improving reimbursement policies. The rapid increase in per capita healthcare spending and the growing public demand for affordable healthcare services are further propelling the expansion of healthcare products, including cancer treatment devices. For instance, the World Economic Forum reported that as of 2022, Russia, Brazil, China, India, and South Africa collectively accounted for one-third of global health expenditures. The World Bank noted that health spending in India and China rose by 3.01% and 5.35%, respectively, from 2018 to 2019. Consequently, the increasing healthcare expenditure in these emerging markets is expected to create favorable conditions for the growth of the proton therapy systems market during the forecast period.
Proton Therapy Systems Market: Segmental Overview
The market is segmented based on setup type into single room and multi-room configurations. The multi-room segment dominated the market in 2022, while the single room segment is projected to experience the highest CAGR throughout the forecast period. In terms of application, the proton therapy systems market is divided into categories including brain and central nervous system cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, gastrointestinal cancer, and others. The brain and central nervous system cancer segment held the largest market share in 2022 and is expected to register the highest CAGR during the forecast period.
Proton Therapy Systems Market: Geographical Overview
The Asia Pacific region is anticipated to exhibit the highest CAGR from 2022 to 2030. Countries such as India and China are seen as having significant potential for the growth of the proton therapy systems market. In 2022, North America held the largest market share, driven by the increasing acceptance and adoption of advanced medical devices, a high prevalence of cancer, and ongoing product innovations by key industry players. The American Cancer Society estimates that the United States recorded approximately 1.95 million new cancer cases and around 0.61 million cancer-related deaths in 2023, marking a notable increase from 1.60 million cases and 0.60 million deaths reported in 2020. According to the Particle Therapy Co-Operative Group, the United States had the highest number of proton therapy systems globally, with 46 treatment facilities by the end of 2023. Thus, the high cancer prevalence and the substantial number of installed proton therapy systems are conducive to the growth of the proton therapy systems market.
Sources
Key primary and secondary sources utilized in the preparation of the report on the proton therapy systems market include data from the World Bank, the National Health Service (NHS), the FDA (Food and Drug Administration), the EMA (European Medicines Agency), and the WHO (World Health Organization).